Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Dermatology
•
Hidradenitis Suppurativa
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
Pt has not responded to Humira or Cosentyx. Pt is declining to have any infusion options.
Related Questions
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
What is your approach to treatment in patients with cutaneous mastocytosis and inflammatory arthritis?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
How would you manage a patient with progressive/refractory molluscum contagiosum who is well controlled on methotrexate for seropositive rheumatoid arthritis?
How would you approach management of a patient who develops squamous cell skin cancer while on abatacept?
Have you utilized JAK inhibitors in patients on dialysis?